Zynex Inc

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Zynex Inc (ZYXI) achieves record highs in Q4 2022

Zynex Inc (ZYXI) delivered strong financial performance in Q4 2022 and full-year 2022, projecting continued growth in 2023. The company's focus on innovation, regulatory milestones, and operational efficiency positions it well for future success.

Zynex Inc reports robust Q1 earnings, eyes revenue growth

Zynex Inc's Q1 2023 performance reflects strong revenue growth and increased orders, supported by strategic initiatives like stock buybacks.
While facing challenges in scaling the sales force and navigating market dynamics, the company is well-positioned to leverage opportunities for expansion and innovation.
Investors can look forward to continued revenue growth, product development, and potential market expansion as Zynex pursues its growth targets.

Zynex Inc reports record revenue and FDA clearances, reaffirms guidance

Zynex Inc delivered robust financial results in Q2 2023, showcasing consistent profitability and revenue growth across its divisions.
The company's focus on product innovation, FDA clearances, and strategic financial moves underscores its commitment to sustained growth and market leadership.
While facing potential challenges, Zynex Inc remains optimistic about its future outlook, aiming to capitalize on market opportunities and drive continued success.

Zynex reports record revenue and growth outlook, driven by innovation

Zynex Inc (ZYXI) delivered strong financial results in Q3 2023, driven by revenue growth, operational efficiency, and strategic product innovations.
The company's focus on noninvasive pain management solutions and commitment to regulatory milestones underscore its growth potential and market positioning.
While facing challenges such as market competition and operational scalability, Zynex's strengths in financial performance and innovation present opportunities for sustained success.

Zynex Inc (ZYXI) reports record revenue and explores strategic alternatives

Zynex Inc (ZYXI) delivered a strong performance in 2023, marked by record revenue, profitability, and operational achievements, positioning the company for continued growth and success.
While facing challenges related to strategic decision-making and operational execution, Zynex remains well-positioned to capitalize on opportunities for revenue expansion, product innovation, and market leadership.
With a focus on financial stability, product diversification, and strategic growth initiatives, Zynex is poised to navigate challenges, leverage opportunities, and drive value for shareholders in the upcoming year.

Zynex Inc reports revenue growth and FDA clearance success

Zynex Inc (ZYXI) demonstrated solid financial performance in Q1 2024, with revenue growth and positive cash flow.
The company's focus on product innovation, sales expansion, and revenue diversification positions it well for future growth.
While facing challenges such as revenue delays and strategic uncertainties, Zynex remains optimistic about its growth prospects and market opportunities.

Zynex Inc reports strong Q2 performance, eyes $200M revenue target

Zynex Inc delivered a strong Q2 2024 performance with revenue growth, improved sales efficiency, and a positive outlook for the year, targeting $200 million in total revenue.
While facing challenges in revenue diversification and sales force refinement, Zynex maintains a solid gross profit margin and a focus on operational excellence.
The company's Monitoring Solutions division shows promise, with ongoing product milestones and plans for FDA submission, indicating future growth potential and market expansion.
Strategic management of challenges and capitalizing on opportunities position Zynex well for sustained growth and profitability in the evolving healthcare market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. It also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

ENGLEWOOD, Colo. , Oct. 12, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 26, 2023 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2023.

Zynex, Inc Sets Third Quarter 2023 Earnings Call

FARO Technologies

Gevo

The Federal Reserve signaling interest rates could stay elevated for the long term coupled with relentless political infighting in Washington has brought another jolt of volatility to equities. This has led to this list of micro-cap stocks to sell.

3 Micro-Cap Stocks to Sell While You Still Can

Zynex, Inc. is a pain management company that manufactures and markets medical devices for chronic and acute pain treatment. The stock has fallen by half since we took a first look at it in April despite being profitable and having better than 20% revenue growth. Is Zynex now in the 'buy zone?" An updated analysis follows in the paragraphs below.

Zynex: A Reassessment

ENGLEWOOD, Colo. , Sept. 19, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming Cantor Global Healthcare Conference, which is being held September 26 th-28th, 2023.

Zynex to Present at the Cantor Global Healthcare Conference

ENGLEWOOD, Colo., Sept. 5, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming H.C.

Zynex to Present at the H.C. Wainwright Global Investment Conference

ENGLEWOOD, Colo. , Aug. 10, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that, since its founding, the company has treated more than 1 million patients through its pain management division.

Zynex Announces 1 Millionth Patient Milestone

ENGLEWOOD, Colo. , Aug. 9, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced the addition of three new therapy products centered around pain management.

Zynex, Inc Announces New Therapy Products

ENGLEWOOD, Colo. , Aug. 3, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has the company's Founder and CEO, Thomas Sandgaard will participate in Benzinga's Pharma Companies vs.

Zynex, Inc Founder and CEO Thomas Sandgaard to participate in Benzinga's Pharma Companies vs. A Tough Macro Backdrop Free Webinar on August 3rd at 12:15 PM ET

Zynex, Inc. (NASDAQ:ZYXI ) Q2 2023 Earnings Conference Call July 27, 2023 4:15 PM ET Company Participants Quinn Callanan - Investor Relations Thomas Sandgaard - Chairman, President and Chief Executive Officer Anna Lucsok - Chief Operating Officer Donald Gregg - Vice President, Zynex Monitoring Solutions Daniel Moorhead - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good day ladies and gentlemen, and welcome to the Zynex Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Zynex, Inc. (ZYXI) Q2 2023 Earnings Call Transcript

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.08 per share a year ago.

Zynex Inc. (ZYXI) Q2 Earnings and Revenues Surpass Estimates

Q2 2023 Revenue increased 22% to $45.0 Million; EPS $0.09 ENGLEWOOD, Colo. , July 27, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has reported its financial and operational results for the second quarter ended June 30, 2023.

Zynex Reports Second Quarter 2023 Financial Results

ENGLEWOOD, Colo. , July 20, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 27, 2023 at 4:15 PM Eastern Time to discuss its financial results for the second quarter, 2023 ended June 30, 2023.

Zynex, Inc. Sets Second Quarter 2023 Earnings Call

ENGLEWOOD, Colo. , July 17, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has won the Top Workplace Award among manufacturers, given by Energage, LLC, an employee engagement technology partner.

Zynex, Inc. (NASD: ZYXI) Wins 2023 National Top Workplaces Award in the Manufacturing Industry Category

Zynex, a medical device manufacturer, has reported a 36% year-over-year increase in revenue in Q1 2023, reaching $42.2 million, with a 14% increase in net income. Despite short-term underperformance, the company shows strong profitability and growth potential, with a gross profit margin of nearly 80% and a substantial return on equity of 24.58%. Zynex's robust growth strategy and commitment to operational efficiency suggest a promising outlook, despite concerns related to its financial stability and stock performance.

Zynex: Strong Growth And Profitability Amid Financial Concerns

ENGLEWOOD, Colo. , July 12, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for second quarter 2023 and reiterated full-year guidance.

Zynex Reports Preliminary Second Quarter 2023 Results

ENGLEWOOD, Colo. , July 10, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has engaged international investor relations specialists MZ Group ("MZ") to lead their comprehensive strategic investor relations and financial communications program across all key markets.

Zynex, Inc. Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

ENGLEWOOD, Colo. , June 20, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the FDA (Food and Drug Administration) has granted 510(k) market clearance for the company's CM-1600 blood and fluid volume monitoring device.

Zynex Receives FDA Clearance of CM-1600 Monitor for Improved Blood and Fluid Management

Zynek makes electrotherapy devices to control pain. The company grew revenue and net income in the first quarter.

Why Shares of Zynex Are Up Wednesday

ENGLEWOOD, Colo. , June 14, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Company's common stock.

Zynex Announces Share Buyback Program

NuScale Power Corp

SurgePays

Cara Therapeutics

CareCloud Inc

Idaho Strategic Resources Inc

TOMI Environmental Solutions

While market advocates will wince at accusations that investing is nothing more than legalized gambling, for these stocks with massive upside potential, I for one will have to concede that only speculators should read ahead. Though these enterprises may have yield lifechanging returns, they can quickly leave you in the poor house.

7 Stocks With 1,000% Upside Potential

ENGLEWOOD, Colo. , May 4, 2023 /PRNewswire/ -- Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), announced today the pricing of its previously announced private offering of $52.5 million aggregate principal amount of 5.00% convertible senior notes due 2026 (the "Notes") in a private offering (the "Notes Offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").

Zynex Prices Upsized $52.5 Million Convertible Senior Notes Offering

ENGLEWOOD, Colo. , May 4, 2023 /PRNewswire/ -- Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), today announced that Thomas Sandgaard, its Chief Executive Officer (the "Selling Stockholder"), has determined not to pursue the public offering of 2,000,000 shares of the Company's common stock that was previously announced on May 3, 2023 (the "Secondary Offering").

Zynex Announces Update Regarding Previously Announced Offerings

ENGLEWOOD, Colo. , May 3, 2023 /PRNewswire/ -- Zynex, Inc. ("Zynex" or "the Company") (Nasdaq: ZYXI), today announced the commencement of an underwritten public offering of 2,000,000 shares of its common stock by Thomas Sandgaard, its Chief Executive Officer (the "Secondary Offering").

Zynex Announces Proposed Secondary Public Offering of Common Stock

ENGLEWOOD, Colo. , May 3, 2023 /PRNewswire/ -- Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), today announced its intent to offer, subject to market conditions and other factors, $50 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes") in a private offering (the "Notes Offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").

Zynex Announces Proposed $50 Million Offering of Convertible Senior Notes

ENGLEWOOD, Colo. , May 3, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has been named by The Denver Post as a winner of Colorado's Top Workplaces 2023 Award.

News for Zynex Inc Stock (ZYXI)